Pfizer Inc. $PFE Shares Bought by BayBridge Capital Group LLC

BayBridge Capital Group LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 4.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 55,714 shares of the biopharmaceutical company’s stock after acquiring an additional 2,564 shares during the period. BayBridge Capital Group LLC’s holdings in Pfizer were worth $1,351,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer during the 1st quarter valued at $27,000. Bayforest Capital Ltd bought a new position in shares of Pfizer during the 1st quarter valued at $28,000. North Capital Inc. acquired a new stake in Pfizer in the 1st quarter worth $28,000. WPG Advisers LLC bought a new position in shares of Pfizer during the 1st quarter worth about $35,000. Finally, Horizon Financial Services LLC bought a new position in shares of Pfizer in the first quarter worth about $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $23.75 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The business’s 50 day moving average price is $24.55 and its 200-day moving average price is $24.13. The company has a market cap of $135.03 billion, a P/E ratio of 12.63, a P/E/G ratio of 0.77 and a beta of 0.55. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same period last year, the business posted $0.60 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on PFE. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Bank of America boosted their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.